Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development

Molecular Oncology

Volumn 9, Issue 5, 2015, Pages 1025-1033

  Jönsson, Bengt ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Clinical trials; Cost effectiveness; Early development; Health technology assessment; Outcome research; Relative effectiveness

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL DEVELOPMENT PLAN; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; DRUG RESEARCH; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE PLANNING; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; OUTCOMES RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; REVIEW; COST BENEFIT ANALYSIS; DRUG DESIGN; ECONOMICS;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84928543902     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.10.009     Document Type: Review

References (23)

1. Berntgen Michael, Gourvil Anne, Pavlovic Mira, Goettsch Wim, Eichler Hans-Georg, Kristensen Finn Børlum Improving the contribution of regulatory assessment reports to health technology assessments-a collaboration between the European medicines agency and the European network for health technology assessment. Value Health 2014, 17(5):634-641.
2. Bonsel G.J., Rutten F.F., Uyl-de Groot C.A. Economicevaluation alongside cancer trials: methodological and practical aspects. Eur. J. Cancer 1993, 29A(Suppl. 7):S10-S14.
3. Booth C.M., Eisenhauer E.A. Progression-free survival: meaningful or simply measurable?. J.Clin. Oncol. 2012, 30(10):1030-1033.
4. Casper J., Schumann-Binarsch S., Kohne C.H. Pazopanib versus sunitinib in renal cancer. N.Engl. J. Med. 2013, 369(20):1969.
5. Davies Andrew, Briggs Andrew, Schneider Dphil John, Levy Adrian, Ebeid Omar, Wagner Samuel, Kotapati Srividya, Ramsey Scott The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res. Med. February 2012, 3(1):e25-e36.
6. Djalalov Sandjar, Beca Jaclyn, Hoch Jeffrey S., Krahn Murray, Tsao Ming-Sound, Cutz Jean-Claude, Leighl Natasha B. Cost-effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. JCO 24 February, 2014.
7. Drummond M.F., Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int. J. Technol. Assess. Health Care 1991, 7(4):561-573.
8. Ekman M.C.C., Ramsberg J., Jonsson L., Sandin R., Jonsson B., Drummond M., Weinstein M.C. PCN162 extrapolation in trial-based cost-effectiveness modeling: in search of a standard. Value Health 2010, 13(7):A282.
9. Elvidge S. EMA's parallel advice workshop bridges regulatory and reimbursement divide. Nat. Rev. Drug Discov. 2013, 13(1):8.
10. EUnetHTA WP5 Relative effectiveness of pharmaceuticals. Pilot Assessment Using the Draft HTA Core Model for Rapid Relative Effectiveness Assessment. Version 4 31 December 2012, Final version. http://www.eunethta.eu/outputs/wp5-ja1-pilot-pazopanib-reportappendix.
11. Glick H.A., Doshi J.A., Sonnad S.S., Polsky D. Economic Evaluation in Clinical Trials 2007, Oxford University Press, New York.
12. Hotte S.J., Bjarnason G.A. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr. Oncol. 2011, 18(Suppl. 2):S11-S19.
13. Ishak K.J., Proskorovsky I., Korytowsky B., Sandin R., Faivre S., Valle J. Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics 2014 Jun, 32(6):533-546.
14. Jönsson L.S.R., Ekman M., Ramsberg J., Charbonneau C., Huang X., Jönsson B., Weinstein M.C., Drummond M. Analyzing overall survival in randomized controlled trials with cross-over and implications for economic evaluation. Value Health 2014, 707-713.
15. Latimer N.R. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med. Decis. Making 2013 Aug, 33(6):743-754.
16. Latimer N.R., Abrams K.R., Lambert P.C., Crowther M.J., Wailoo A.J., Morden J.P., Akehurst R.L., Campbell M.J. Adjusting survival time estimates to account for treatment switching in randomized controlled trials-an economic evaluation context: methods, limitations, and recommendations. Med. Decis. Making 2014 Apr, 34(3):387-402.
17. Lauer M.S., D'Agostino R.B. The randomized registry trial-the next disruptive technology in clinical research?. N.Engl. J. Med. 2013 Oct 24, 369(17):1579-1581.
18. Lee S., Earle C., Weeks J.C. Outcomes research in oncology: history, conceptual framework, and trends in the literature. J.Natl. Cancer Inst. 2000, 92:195-204.
19. Luce B., Drummond M., Dubois R.W., Neumann P.J., Jönsson B., Siebert U., et al. Principles for planning and conducting comparative effectiveness research. J.Comp. Effectiveness Res. 2012, 1:431-440.
20. Neumann P.J., Cohen J.T., Weinstein M.C. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N.Engl. J. Med. 2014, 371(9):796-797.
21. Ramsey Scott D., Moinpour Carol M., Lovato Laura C., Crowley John J., Grevstad Patra, Presant Cary A., Rivkin Saul E., Kelly Karen, Gandara David R. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J.Natl. Cancer Inst. February 20, 2002, 94(4).
22. Ramsey Scott, Willke Richard, Briggs Andrew, Brown Ruth, Buxton Martin, Chawla Anita, Cook John, Glick Henry, Liljas Bengt, Petitti Diana, Reed Shelby Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health 2005, 5:521-533.
23. Shih Ya-Chen Tina, Mullins Daniel C., Drummond Michael The role of economic evaluation in meeting IOM's recommendations on delivering high-quality cancer care. Value Health 2014, 17:497-500.